Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Nuformix Executive Chair Alastair Riddell resigns after one year

Tue, 31st May 2022 12:41

(Alliance News) - Nuformix PLC on Tuesday said Executive Chair Alastair Riddell has resigned with immediate effect.

Riddell joined the London-based pharmaceutical development company as non-executive chair in May last year. He was promoted to executive chair in December.

Nuformix said that Riddell is taking up a full-time executive role with another company. Riddell has been part of Nuformix as chair for a year since 2021.

Non-Executive Director Julian Gilbert said: "The management requirements for the business will be considered and further updates provided in due course."

Shares in Nuformix were down 2.0% to 0.50 pence each in London on Tuesday morning.

By Sophie Rose; sophierose@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Related Shares

More News
12 Mar 2024 14:30

UK shareholder meetings calendar - next 7 days

1 Mar 2024 10:31

IN BRIEF: Nuformix announces subscription to raise GBP150,000

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Announce intention to raise gross proceeds of GBP...

3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months th...

23 Oct 2023 12:38

Nuformix gets patent in Japan for pulmonary fibrosis treatment NXP002

(Alliance News) - Nuformix PLC on Monday said it has been issued with a patent in Japan for NXP002, its potential novel inhaled treatment for idiopath...

18 Sep 2023 10:20

IN BRIEF: Nuformix to receive milestone payments from Oxilio pact

Nuformix PLC - London-based pharmaceutical development company targeting unmet medical needs in fibrosis and oncology - Says it will receive immediate...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.